Premium
Diagnostic and Follow‐up Studies on CEA, AFP and ALP 4 Isoenzyme in the Sera of Gynecological Malignancies
Author(s) -
TOTTORI K.,
SATO Y.,
TAKEUCHI S.
Publication year - 1978
Publication title -
scandinavian journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.934
H-Index - 88
eISSN - 1365-3083
pISSN - 0300-9475
DOI - 10.1111/j.1365-3083.1978.tb03973.x
Subject(s) - medicine , gastroenterology , stage (stratigraphy) , carcinoma , cervical carcinoma , pathology , cervical cancer , cancer , biology , paleontology
Simultaneous determination of CEA, AFP and ALP 4 was made in patients with various gynecological malignancies. CEA was positive in 65%, AFP was positive in 1.8% of 55 cases with cervical carcinoma stage 0—‐II. ALP 4 was positive in one patient in these stages. In the group of cervical carcinoma stage III, stage IV and recurrence, CEA and AFP were positive in 100% and in 8.6% of 35 cases respectively. ALP 4 was positive in 14.3%. High levels and/or progressively increasing CEA with positive ALP 4 were found to be significant in poor prognostic patients in whom ALP 4 was not always found positive. Out of 17 cases with endometrial carcinoma, CEA was positive in 12 patients. AFP and ALP 4 were each positive in one case. Of 30 cases with ovarian carcinoma, CEA was positive in 70%, AFP in 23% and ALP 4 in 14%. Increasing CEA and/or increasing AFP appeared to be correlated with poor prognosis. In the group of 5 vulvar carcinoma, only CEA was positive in 80% of the patients. Of 19 cases of choriocarcinoma, CEA was positive in 11%, AFP was positive in 5.3% and ALP 4 was positive in 5.6%. There existed reverse‐correlation between serum CEA and AFP in some cases.